Please ensure Javascript is enabled for purposes of website accessibility

Why TransEnterix Shares Sky-Rocketed 33% Today

By Todd Campbell - Jan 27, 2016 at 1:41PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Rumors of a potential suitor sent this tiny company's shares soaring.

Image source: TransEnterix.

What: Following rumors that Johnson & Johnson (JNJ -0.01%) may consider acquiring it, shares in TransEnterix (ASXC -1.79%) soared by 33% at 1:00 p.m. ET. 

So what: TranEnterix, is a tiny maker of surgical devices that hopes to challenge much larger robotic surgery Goliath Intuitive Surgical (ISRG -2.61%) someday.

The company is developing robotic devices that can assist in minimally invasive surgery, and its plans include a potential U.S. launch of SurgiBot in the second quarter of this year, and a launch of ALF-X in various countries that accept the CE Mark of approval.

Because Johnson & Johnson has a large medical device division that's seen its sales flat-line, its management has indicated plans to restructure and conduct M&A, and it's already announced a collaboration to work with Alphabet (GOOG -0.54%) on robotic surgical devices, investors are speculating that TransEnterix could be on the company's wish list.

Now what: Trafficking in rumors is a sure-fire way to come up on the losing end of an investment, so investors may want to shy away from putting too much stock in the validity of this report.

Nevertheless, investors may want to add TransEnterix's to their watchlist and track its progress, because the company did recently hire former Intuitive Surgical sales leaders to spearhead their commercialization efforts, and the market is big and growing. For example, Intuitive Surgical sales increased 12% to $2.38 billion in 2015.

Overall, while there's a market opportunity that makes this company interesting, the fact that TransEnterix doesn't have any revenue yet and it still loses money makes me content to key an eye on it, rather than jump in and buy shares on this pop.

Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool's board of directors. Todd Campbell has no position in any stocks mentioned. Todd owns E.B. Capital Markets, LLC. E.B. Capital's clients may have positions in the companies mentioned. The Motley Fool owns shares of and recommends Alphabet (C shares) and Intuitive Surgical. The Motley Fool recommends Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Johnson & Johnson Stock Quote
Johnson & Johnson
JNJ
$170.18 (-0.01%) $0.02
Intuitive Surgical, Inc. Stock Quote
Intuitive Surgical, Inc.
ISRG
$232.88 (-2.61%) $-6.25
Alphabet Inc. Stock Quote
Alphabet Inc.
GOOG
$117.50 (-0.54%) $0.64
Asensus Surgical, Inc. Stock Quote
Asensus Surgical, Inc.
ASXC
$0.55 (-1.79%) $0.01

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
379%
 
S&P 500 Returns
123%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/10/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.